SCHEMBL1705261

SCHEMBL1705261

CN(Cc1ccncc1)C1CCC(Oc2ccc3cnccc3c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 4/20 0.51
ROCK1 Q13464 4/20 0.51
PRKCZ Q05513 1/20 0.50
ROCK2 O75116 1/20 0.48
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PRMT3 O60678 2/20 0.38
HRH3 Q9Y5N1 3/20 0.38
CYP3A4 P08684 1/20 0.38
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
CHUK O15111 2/20 0.36
HRH4 Q9H3N8 1/20 0.35
PDE4A P27815 1/20 0.35
LCK P06239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1705004 0.93 ROCK1 (0.57) IKBKBROCK1PRKCZROCK2KDM4E
SCHEMBL1705001 0.93 ROCK1 (0.57) IKBKBROCK1PRKCZROCK2KDM4E
SCHEMBL1705239 0.93 ROCK1 (0.57) IKBKBROCK1PRKCZROCK2KDM4E
SCHEMBL1705052 0.86 IKBKB (0.49) IKBKBROCK1PRKCZROCK2ALDH1A1
SCHEMBL1754939 0.84 IKBKB (0.59) IKBKBROCK1PRKCZROCK2PRMT3
SCHEMBL1705083 0.84 IKBKB (0.59) IKBKBROCK1PRKCZROCK2PRMT3
SCHEMBL1705054 0.84 IKBKB (0.59) IKBKBROCK1PRKCZROCK2PRMT3
SCHEMBL1705062 0.84 IKBKB (0.59) IKBKBROCK1PRKCZROCK2PRMT3
SCHEMBL1705056 0.84 IKBKB (0.59) IKBKBROCK1PRKCZROCK2PRMT3
SCHEMBL1705084 0.84 IKBKB (0.59) IKBKBROCK1PRKCZROCK2PRMT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US claimed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP claimed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives MYLK2, MYLK, MYLK3 IKBKB 1991/4885ROCK1 8/4885PRKCZ 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.